Last reviewed · How we verify
Treatment as Usual (TAU)
Treatment as Usual (TAU) is a control or comparator arm in clinical trials that represents standard clinical care without the investigational intervention.
At a glance
| Generic name | Treatment as Usual (TAU) |
|---|---|
| Also known as | Antibiotics and steroids, standard of care treatment with FDA-approved psychotropic drugs, Control Group |
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
TAU is not a drug but rather a study design element used in clinical trials to establish a baseline for efficacy and safety comparisons. It consists of the standard medical management and therapeutic approaches that would normally be provided to patients with a given condition, allowing researchers to measure the incremental benefit of the investigational treatment.
Approved indications
Common side effects
Key clinical trials
- A Brief Case Management Intervention to Promote Personal Recovery and Prevent Psychiatric Involuntary Readmissions: a Randomised Controlled Trial (NA)
- The Effects of Mindfulness-based Cognitive Therapy in People With Parkinson's Disease (NA)
- The Trans-Led Care Study (NA)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders (NA)
- Cognitive Stimulation in Older Adults With Alzheimer's Disease (NA)
- Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community (NA)
- Re-Engineered Discharge for Diabetes Care Transitions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment as Usual (TAU) CI brief — competitive landscape report
- Treatment as Usual (TAU) updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI